Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: Placebo-controlled study
Autore:
Ueki, Y; Matsumoto, K; Kizaki, Y; Yoshida, K; Matsunaga, Y; Yano, M; Miyake, S; Tominaga, Y; Eguchi, K;
Indirizzi:
Sasebo Chuo Hosp, Dept Internal Med, Sasebo 8571195, Japan Sasebo Chuo Hosp Sasebo Japan 8571195 nternal Med, Sasebo 8571195, Japan Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 852, Japan Nagasaki Univ Nagasaki Japan 852 ept Internal Med 1, Nagasaki 852, Japan
Titolo Testata:
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
fascicolo: 2, volume: 8, anno: 1999,
pagine: 131 - 137
SICI:
0929-5305(199908)8:2<131:AINOLI>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
SYNTHETIC THROMBIN INHIBITOR; DISSEMINATED INTRAVASCULAR COAGULATION; RELAXING FACTOR; BLOOD; ENDOTHELIUM; HEMOGLOBIN; METABOLISM; ADHESION; NITRATE; CELLS;
Keywords:
argatroban; nitric oxide; HbNO; microcirculation; PAOD;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Ueki, Y Sasebo Chuo Hosp, Dept Internal Med, Yamato Cho 15, Sasebo 8571195, Japan Sasebo Chuo Hosp Yamato Cho 15 Sasebo Japan 8571195 571195, Japan
Citazione:
Y. Ueki et al., "Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: Placebo-controlled study", J THROMB TH, 8(2), 1999, pp. 131-137

Abstract

Intravenous argatroban infusion therapy is widely used for the restorationof peripheral microcirculation in patients with peripheral arterial obstructive disease (PAOD). We investigated the effect of argatroban infusion therapy on plasma levels of nitric oxide (NO) and nitrosyl-hemoglobin (HbNO) in patients with PAOD compared with a placebo-treated PAOD group. The chemiluminescence method was used to determine plasma NO and HbNO. Argatroban wasadministered as a continuous intravenous infusion for 60 minutes and repeated daily over a period of 2 weeks in 10 patients with PAOD. Treatment significantly improved the clinical signs and symptoms. Serial thermograms showed a 1-2 degrees C rise in the temperature of the affected legs in all patients immediately after intravenous argatroban infusion therapy. Enhancementof the peripheral circulation was maintained after the end of argatroban infusion for up to 90 minutes despite elimination of argatroban from the circulation. Furthermore, there was a progressive and significant increase in the mean concentration of plasma NO in PAOD patients after commencement of argatroban infusion (baseline, 58.0 +/- 13.7;90 minutes after infusion, 65.7 +/- 13.4 mu M; P < 0.01). HbNO significantly increased from a baseline value of 1063 +/- 126 to 1460 +/- 250 nM at 30 minutes after infusion (P, 0.01). However, the level of HbNO decreased thereafter, although it remained significantly elevated, even at 90 minutes after the end of argatroban infusion. Our results suggest that argatroban may lead to increased HbNO and plasma NO, and this may contribute to the improved microcirculation in PAOD patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 18:25:58